rs373082402
Variant summary
Our verdict is Likely benign. The variant received -5 ACMG points: 0P and 5B. BP4_StrongBP6
The NM_000626.4(CD79B):c.250G>A(p.Glu84Lys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000483 in 1,614,070 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 17/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000626.4 missense
Scores
Clinical Significance
Conservation
Publications
- agammaglobulinemia 6, autosomal recessiveInheritance: AR Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), ClinGen
- autosomal agammaglobulinemiaInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -5 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| CD79B | NM_000626.4 | c.250G>A | p.Glu84Lys | missense_variant | Exon 3 of 6 | ENST00000006750.8 | NP_000617.1 | |
| CD79B | NM_001039933.3 | c.253G>A | p.Glu85Lys | missense_variant | Exon 3 of 6 | NP_001035022.1 | ||
| CD79B | NM_001329050.2 | c.122-366G>A | intron_variant | Intron 2 of 4 | NP_001315979.1 | |||
| CD79B | NM_021602.4 | c.119-366G>A | intron_variant | Intron 2 of 4 | NP_067613.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| CD79B | ENST00000006750.8 | c.250G>A | p.Glu84Lys | missense_variant | Exon 3 of 6 | 1 | NM_000626.4 | ENSP00000006750.4 | ||
| ENSG00000285947 | ENST00000647774.1 | c.50-366G>A | intron_variant | Intron 1 of 7 | ENSP00000497443.1 |
Frequencies
GnomAD3 genomes AF: 0.000138 AC: 21AN: 152212Hom.: 0 Cov.: 33 show subpopulations
GnomAD2 exomes AF: 0.0000477 AC: 12AN: 251400 AF XY: 0.0000294 show subpopulations
GnomAD4 exome AF: 0.0000390 AC: 57AN: 1461858Hom.: 0 Cov.: 34 AF XY: 0.0000371 AC XY: 27AN XY: 727238 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.000138 AC: 21AN: 152212Hom.: 0 Cov.: 33 AF XY: 0.000148 AC XY: 11AN XY: 74362 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Agammaglobulinemia 6, autosomal recessive Uncertain:2
- -
This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 84 of the CD79B protein (p.Glu84Lys). This variant is present in population databases (rs373082402, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with CD79B-related conditions. ClinVar contains an entry for this variant (Variation ID: 567186). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available". The lysine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
not specified Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at